Ellington Management Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ellington Management Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-11,700	Closed	-$319K	–	838
2019 Q3	$319K	Buy	+11,700	New	+$303K	0.06%	349
2019 Q2	–	Sell	-12,800	Closed	-$338K	–	883
2019 Q1	$338K	Buy	+12,800	New	+$303K	0.06%	326
2014 Q3	–	Sell	-12,600	Closed	-$199K	–	534
2014 Q2	$199K	Buy	+12,600	New	+$180K	0.09%	364
2014 Q1	–	Sell	-48,800	Closed	-$372K	–	834
2013 Q4	$372K	Buy	+48,800	New	+$263K	0.13%	253

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ellington Management Group's HZNP Position: Q4 2019 in Review

Ellington Management Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2019, closing a stake of 11,700 shares — an estimated $319K sold.

Ellington Management Group first reported a position in HZNP in Q4 2013 and held it in 4 quarters. The position peaked at $372K in Q4 2013. 281 funds tracked by Wall St. Rank hold HZNP as of Q4 2019.

Ellington Management Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2019 after selling out during the quarter.
Ellington Management Group sold 11,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2019, an estimated $319K.
Ellington Management Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 4 quarters.
Ellington Management Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $372K in Q4 2013.
281 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2019.

Based on Ellington Management Group's 13F filing for Q4 2019, filed 14 Feb 2020.